Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1129-2377
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study ; volume:19 ; number:1 ; day:15 ; month:8 ; year:2018 ; pages:1-8 ; date:12.2018
The journal of headache and pain ; 19, Heft 1 (15.8.2018), 1-8, 12.2018
- Creator
-
Landy, Stephen
- Contributor
-
Munjal, Sagar
Brand-Schieber, Elimor
Rapoport, Alan M.
SpringerLink (Online service)
- DOI
-
10.1186/s10194-018-0882-y
- URN
-
urn:nbn:de:101:1-2018090310161042468895
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Landy, Stephen
- Munjal, Sagar
- Brand-Schieber, Elimor
- Rapoport, Alan M.
- SpringerLink (Online service)
Other Objects (12)
Episodic Migraine and Older Adults
A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine
Sex and Gender Considerations in Episodic Migraine
Pediatric migraine and episodic syndromes that may be associated with migraine
Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study
Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study
Alterations in pain processing circuitries in episodic migraine
Cerebral neurocysticercosis mimicking or comorbid with episodic migraine?
Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial
dfN
The Gut-brain Connection and Episodic Migraine: an Update
Nonspecific periaqueductal gray lesions on T2WI in episodic migraine
Episodic Migraine and Older Adults
A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine
Sex and Gender Considerations in Episodic Migraine
Pediatric migraine and episodic syndromes that may be associated with migraine
Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study
Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study
Alterations in pain processing circuitries in episodic migraine
Cerebral neurocysticercosis mimicking or comorbid with episodic migraine?
Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial
dfN
The Gut-brain Connection and Episodic Migraine: an Update
Nonspecific periaqueductal gray lesions on T2WI in episodic migraine
Episodic Migraine and Older Adults
A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine
Sex and Gender Considerations in Episodic Migraine
Pediatric migraine and episodic syndromes that may be associated with migraine
Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study
Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study
Alterations in pain processing circuitries in episodic migraine
Cerebral neurocysticercosis mimicking or comorbid with episodic migraine?
Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial
dfN
The Gut-brain Connection and Episodic Migraine: an Update